This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
The Medicines Company (MDCO - Analyst Report) recently received good news with the company announcing positive results on its phase III candidate, cangrelor. Cangrelor is being developed for the prevention of platelet activation and aggregation that leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention (PCI).
As compared to Bristol-Myers Squibb / Sanofi’s (BMY - Analyst Report)/(SNY - Analyst Report) Plavix (clopidogrel), cangrelor showed a statistically significant improvement in the CHAMPION PHOENIX study. Safety results were same as seen in prior trials. Cangrelor is quick in action and instantly reversible and thus it is expected to play an important role in patients undergoing PCI and those who need to discontinue oral P2Y12 inhibitors ahead of surgery. The company intends to submit data from the CHAMPION PHOENIX and BRIDGE studies and seek marketing approval in the US and EU this year.
We are encouraged by The Medicines Company’s progress with its pipeline. This is the second positive development on the pipeline front at The Medicines Company. A few weeks back, the company had announced positive results on its phase III antibiotic candidate, oritavancin. Oritavancin was being evaluated in the phase III SOLO-1 study for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.
With The Medicines Company reporting positive results from the SOLO-1 study, the company is now planning to complete enrolment for the SOLO-2 study in the first half of 2013. Results should be out shortly thereafter. Both studies will be used to support regulatory filings in the US and the EU.
Please login to Zacks.com or register to post a comment.